Lut Van Damme

Summary

Publications

  1. pmc Preexposure prophylaxis for HIV infection among African women
    Lut Van Damme
    FHI 360, Research Triangle Park, North Carolina, USA
    N Engl J Med 367:411-22. 2012
  2. doi request reprint Current status of topical antiretroviral chemoprophylaxis
    Lut Van Damme
    Department of Clinical Sciences, FHI 360, Washington DC, USA
    Curr Opin HIV AIDS 7:520-5. 2012
  3. pmc Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial
    Fernand A Guédou
    URESP, Centre de recherche FQRS du CHU de Québec, Departement de Medecine sociale et preventive, Universite Laval, Quebec, Canada
    BMC Infect Dis 13:208. 2013
  4. doi request reprint Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP
    Amy Corneli
    Social and Behavioral Health Sciences, FHI 360, Durham, NC Quantitative Sciences, FHI 360, Durham, NC Impact Research and Development Organization, Kisumu, Kenya Setshaba Research Centre, Soshanguve, South Africa Josha Research, Bloemfontein, South Africa and Clinical Sciences, FHI 360, Durham, NC Dr Van Damme is now with The Bill and Melinda Gates Foundation, Seattle, WA
    J Acquir Immune Defic Syndr 67:555-63. 2014
  5. pmc Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial
    Justin Mandala
    FHI 360, 1825 Connecticut Ave, Suite 800, NW, Washington, DC 20009, USA
    BMC Pharmacol Toxicol 15:77. 2014
  6. pmc The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South Africa
    Jennifer Headley
    FHI 360, Durham, North Carolina, United States of America
    PLoS ONE 9:e106410. 2014
  7. doi request reprint Predictors of pregnancy in microbicide trials
    Vera Halpern
    FHI, P O Box 13950, Research Triangle Park, NC 27709, USA
    Contraception 83:436-40. 2011
  8. ncbi request reprint Baseline factors associated with incident HIV and STI in four microbicide trials
    Paul J Feldblum
    Family Health International, Research Triangle Park, NC 27709, USA
    Sex Transm Dis 37:594-601. 2010

Collaborators

Detail Information

Publications8

  1. pmc Preexposure prophylaxis for HIV infection among African women
    Lut Van Damme
    FHI 360, Research Triangle Park, North Carolina, USA
    N Engl J Med 367:411-22. 2012
    ..Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others...
  2. doi request reprint Current status of topical antiretroviral chemoprophylaxis
    Lut Van Damme
    Department of Clinical Sciences, FHI 360, Washington DC, USA
    Curr Opin HIV AIDS 7:520-5. 2012
    ..This review examines these developments...
  3. pmc Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial
    Fernand A Guédou
    URESP, Centre de recherche FQRS du CHU de Québec, Departement de Medecine sociale et preventive, Universite Laval, Quebec, Canada
    BMC Infect Dis 13:208. 2013
    ..Data on risk factors of recurrent bacterial vaginosis (RBV) are still scarce. We used data from female sex workers (FSW) participating in a randomized controlled microbicide trial to examine predictors of BV recurrence...
  4. doi request reprint Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP
    Amy Corneli
    Social and Behavioral Health Sciences, FHI 360, Durham, NC Quantitative Sciences, FHI 360, Durham, NC Impact Research and Development Organization, Kisumu, Kenya Setshaba Research Centre, Soshanguve, South Africa Josha Research, Bloemfontein, South Africa and Clinical Sciences, FHI 360, Durham, NC Dr Van Damme is now with The Bill and Melinda Gates Foundation, Seattle, WA
    J Acquir Immune Defic Syndr 67:555-63. 2014
    ..We hypothesized that one reason for the poor adherence was low perceived HIV risk...
  5. pmc Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial
    Justin Mandala
    FHI 360, 1825 Connecticut Ave, Suite 800, NW, Washington, DC 20009, USA
    BMC Pharmacol Toxicol 15:77. 2014
    ....
  6. pmc The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South Africa
    Jennifer Headley
    FHI 360, Durham, North Carolina, United States of America
    PLoS ONE 9:e106410. 2014
    ..Incidence rates in the FEM-PrEP and VOICE trials demonstrate that women from diverse sub-Saharan African communities continue to be at substantial HIV risk...
  7. doi request reprint Predictors of pregnancy in microbicide trials
    Vera Halpern
    FHI, P O Box 13950, Research Triangle Park, NC 27709, USA
    Contraception 83:436-40. 2011
    ..We performed this analysis to identify baseline participant characteristics associated with increased risk of pregnancy in recent vaginal microbicide trials...
  8. ncbi request reprint Baseline factors associated with incident HIV and STI in four microbicide trials
    Paul J Feldblum
    Family Health International, Research Triangle Park, NC 27709, USA
    Sex Transm Dis 37:594-601. 2010
    ....